CYP2D6 genotype should not be used for deciding about tamoxifen therapy in postmenopausal breast cancer

Journal of Clinical Oncology

Volumn 31, Issue 21, 2013, Pages 2753-2755

  Rae, James M ^a   Regan, Meredith ^b   Leyland Jones, Brian ^c   Hayes, Daniel F ^a   Dowsett, Mitch ^d  

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c SANFORD RESEARCH   (United States)

^d ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2D6; ENDOXIFEN; ESTROGEN RECEPTOR; FULVESTRANT; TAMOXIFEN;

ALLELE; BREAST CANCER; CLINICAL DECISION MAKING; CLINICAL TRIAL (TOPIC); ENDOPLASMIC RETICULUM; GENE MAPPING; GENOTYPE; HETEROZYGOSITY LOSS; LETTER; PHARMACOGENETICS; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN DEGRADATION;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CYTOCHROME P-450 CYP2D6; FEMALE; HUMANS; POSTMENOPAUSE; TAMOXIFEN;

EID: 84890502047     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.49.4278     Document Type: Letter

References (15)

1. Brauch H, Schroth W, Goetz MP, et al: Tamoxifen use in postmenopausal breast cancer: CYP2D6 matters. J Clin Oncol 31:176-180, 2013
2. Regan MM, Leyland-Jones B, Bouzyk M, et al: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: The Breast International Group 1-98 Trial. J Natl Cancer Inst 104:441-451, 2012
3. Rae JM, Drury S, Hayes DF, et al: CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J Natl Cancer Inst 104:452-460, 2012
4. Castells A, Gusella JF, Ramesh V, et al: A region of deletion on chromosome 22q13 is common to human breast and colorectal cancers. Cancer Res 60:2836-2839, 2000
5. Hirano A, Emi M, Tsuneizumi M, et al: Allelic losses of loci at 3p25.1, 8p22, 13q12, 17p13.3, and 22q13 correlate with postoperative recurrence in breast cancer. Clin Cancer Res 7:876-882, 2001
6. Loo LW, Ton C, Wang YW, et al: Differential patterns of allelic loss in estrogen receptor-positive infiltrating lobular and ductal breast cancer. Genes Chromosomes Cancer 47:1049-1066, 2008
7. Cancer Genome Atlas Network: Comprehensive molecular portraits of human breast tumours. Nature 490:61-70, 2012
8. Curtis C, Shah SP, Chin SF, et al: The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486:346- 352, 2012
9. Goetz MP, Rae JM, Suman VJ, et al: Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 23:9312-9318, 2005
10. Schroth W, Antoniadou L, Fritz P, et al: Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol 25:5187-5193, 2007
11. Schroth W, Goetz MP, Hamann U, et al: Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA 302:1429-1436, 2009
12. Simon RM, Paik S, Hayes DF: Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 101:1446-1452, 2009
13. Institute of Medicine of the National Academies: Evolution of Translational Omics: Lessons Learned and the Path Forward. Washington, DC, The National Academies Press, 2012
14. Wu X, Hawse JR, Subramaniam M, et al: The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cells. Cancer Res 69:1722-1727, 2009
15. Robertson JF, Nicholson RI, Bundred NJ, et al: Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl) -nonyl]estra-1,3,5, (10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer. Cancer Res 61:6739-6746, 2001